# NAFLD Among Patients With Type 2 Diabetes and CKD

> **NCT03826381** · — · COMPLETED · sponsor: **Rigshospitalet, Denmark** · enrollment: 100 (actual)

## Conditions studied

- Non-Alcoholic Fatty Liver Disease
- Chronic Kidney Diseases
- Type2 Diabetes

## Interventions

- **DIAGNOSTIC_TEST:** Magnetic resonance (MR) spectroscopy of the liver
- **DIAGNOSTIC_TEST:** Fibroscan
- **DEVICE:** Continuous glucose monitoring (CGM) for four days.
- **RADIATION:** Dual Energy X-ray Absorptiometry (DEXA) scan
- **BIOLOGICAL:** Blood samples
- **OTHER:** Clinical and demographic data

## Key facts

- **NCT ID:** NCT03826381
- **Lead sponsor:** Rigshospitalet, Denmark
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-06
- **Primary completion:** 2021-06-23
- **Final completion:** 2021-06-23
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2021-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03826381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03826381, "NAFLD Among Patients With Type 2 Diabetes and CKD". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT03826381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*